Aligos Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue from collaborations | $9,338 | $13,907 |
| Revenue from customers | 6,191 | — |
| Operating expenses: | ||
| Research and development | 73,040 | 85,077 |
| General and administrative | 30,616 | 26,410 |
| Total operating expenses | 103,656 | 111,487 |
| Loss from operations | (88,127) | (97,580) |
| Interest and other income, net | 1,243 | 1,640 |
| Loss before income tax expense | (86,884) | (95,940) |
| Income tax expense | (795) | (106) |
| Net loss | (87,679) | (96,046) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | 96 | (57) |
| Gains on pension plans | 48 | 6 |
| Other comprehensive income (loss) | 144 | (51) |
| Comprehensive loss | $(87,535) | $(96,097) |
| Net loss per share, basic and diluted | $(1.36) | $(2.25) |
| Weighted average shares of common stock, basic and diluted | 64,260,588 | 42,695,227 |
Consolidated Statements of Changes in
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.